{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T18:29:04Z","timestamp":1760898544470},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Capital Health Research and Development of Special Grant","award":["No. 2020-2-2093"],"award-info":[{"award-number":["No. 2020-2-2093"]}]},{"name":"the Special Fund of The Pediatric Medical Coordinated Development Center of Beijing Hospitals Authority","award":["No.XTZD20180201"],"award-info":[{"award-number":["No.XTZD20180201"]}]},{"name":"National Science and Technology Key Projects","award":["No. 2017ZX09304029004"],"award-info":[{"award-number":["No. 2017ZX09304029004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s11102-021-01176-x","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T15:02:50Z","timestamp":1627138970000},"page":"108-115","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Second-line regimen for CNS-involved pediatric Langerhans cell histiocytosis"],"prefix":"10.1007","volume":"25","author":[{"given":"Hongyun","family":"Lian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,24]]},"reference":[{"issue":"4","key":"1176_CR1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/ped.12380","volume":"56","author":"A Morimoto","year":"2014","unstructured":"Morimoto A, Oh Y, Shioda Y, Kudo K, Imamura T (2014) Recent advances in Langerhans cell histiocytosis. Pediatr Int Off J Jpn Pediatr Soc 56(4):451\u2013461. https:\/\/doi.org\/10.1111\/ped.12380","journal-title":"Pediatr Int Off J Jpn Pediatr Soc"},{"issue":"1","key":"1176_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bjh.13247","volume":"169","author":"ML Berres","year":"2015","unstructured":"Berres ML, Merad M, Allen CE (2015) Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol 169(1):3\u201313. https:\/\/doi.org\/10.1111\/bjh.13247","journal-title":"Br J Haematol"},{"issue":"2","key":"1176_CR3","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/S1470-2045(17)30031-1","volume":"18","author":"J Haroche","year":"2017","unstructured":"Haroche J, Cohen-Aubart F, Rollins BJ, Donadieu J, Charlotte F, Idbaih A et al (2017) Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol 18(2):e113\u2013e125. https:\/\/doi.org\/10.1016\/S1470-2045(17)30031-1","journal-title":"Lancet Oncol"},{"issue":"2","key":"1176_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/pbc.24367","volume":"60","author":"R Haupt","year":"2013","unstructured":"Haupt R, Minkov M, Astigarraga I, Schafer E, Nanduri V, Jubran R et al (2013) Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer 60(2):175\u2013184. https:\/\/doi.org\/10.1002\/pbc.24367","journal-title":"Pediatr Blood Cancer"},{"issue":"22","key":"1176_CR5","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","volume":"127","author":"JF Emile","year":"2016","unstructured":"Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J et al (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127(22):2672\u20132681. https:\/\/doi.org\/10.1182\/blood-2016-01-690636","journal-title":"Blood"},{"issue":"5","key":"1176_CR6","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.hoc.2015.06.005","volume":"29","author":"C Monsereenusorn","year":"2015","unstructured":"Monsereenusorn C, Rodriguez-Galindo C (2015) Clinical characteristics and treatment of langerhans cell histiocytosis. Hematol Oncol Clin North Am 29(5):853\u2013873. https:\/\/doi.org\/10.1016\/j.hoc.2015.06.005","journal-title":"Hematol Oncol Clin North Am"},{"key":"1176_CR7","volume-title":"Langerhans cell histiocytosis. Evaluation and treatment guidelines","author":"Histiocyte Society","year":"2009","unstructured":"Histiocyte Society (2009) Langerhans cell histiocytosis. Evaluation and treatment guidelines. Histiocyte Society, Pitman"},{"issue":"4","key":"1176_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/mpo.2950240407","volume":"24","author":"N Grois","year":"1995","unstructured":"Grois N, Flucher-Wolfram B, Heitger A, Mostbeck GH, Hofmann J, Gadner H (1995) Diabetes insipidus in Langerhans cell histiocytosis: results from the DAL-HX 83 study. Med Pediatr Oncol 24(4):248\u2013256. https:\/\/doi.org\/10.1002\/mpo.2950240407","journal-title":"Med Pediatr Oncol"},{"issue":"5","key":"1176_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1067\/mpd.2001.111331","volume":"138","author":"H Gadner","year":"2001","unstructured":"Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A et al (2001) A randomized trial of treatment for multisystem Langerhans\u2019 cell histiocytosis. J Pediatr 138(5):728\u2013734. https:\/\/doi.org\/10.1067\/mpd.2001.111331","journal-title":"J Pediatr"},{"issue":"6","key":"1176_CR10","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/bjh.14140","volume":"174","author":"C Rigaud","year":"2016","unstructured":"Rigaud C, Barkaoui MA, Thomas C, Bertrand Y, Lambilliotte A, Miron J et al (2016) Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol 174(6):887\u2013898. https:\/\/doi.org\/10.1111\/bjh.14140","journal-title":"Br J Haematol"},{"issue":"25","key":"1176_CR11","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","volume":"121","author":"H Gadner","year":"2013","unstructured":"Gadner H, Minkov M, Grois N, P\u00f6tschger U, Thiem E, Aric\u00f2 M et al (2013) Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood 121(25):5006\u20135014","journal-title":"Blood"},{"issue":"4","key":"1176_CR12","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1210\/jcem.85.4.6501","volume":"85","author":"GA Kaltsas","year":"2000","unstructured":"Kaltsas GA, Powles TB, Evanson J, Plowman PN, Drinkwater JE, Jenkins PJ et al (2000) Hypothalamo-pituitary abnormalities in adult patients with Langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab 85(4):1370\u20131376. https:\/\/doi.org\/10.1210\/jcem.85.4.6501","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1176_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2014-12-569301","volume":"126","author":"CE Allen","year":"2015","unstructured":"Allen CE, Ladisch S, McClain KL (2015) How I treat Langerhans cell histiocytosis. Blood 126(1):26\u201335. https:\/\/doi.org\/10.1182\/blood-2014-12-569301","journal-title":"Blood"},{"issue":"1","key":"1176_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12185-016-1993-3","volume":"104","author":"A Morimoto","year":"2016","unstructured":"Morimoto A, Shioda Y, Imamura T, Kudo K, Kawaguchi H, Sakashita K et al (2016) Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol 104(1):99\u2013109. https:\/\/doi.org\/10.1007\/s12185-016-1993-3","journal-title":"Int J Hematol"},{"issue":"1","key":"1176_CR15","doi-asserted-by":"publisher","first-page":"e27454","DOI":"10.1002\/pbc.27454","volume":"66","author":"K Sakamoto","year":"2019","unstructured":"Sakamoto K, Morimoto A, Shioda Y, Imamura T, Imashuku S (2019) Central diabetes insipidus in pediatric patients with Langerhans cell histiocytosis: results from the JLSG-96\/02 studies. Pediatr Blood Cancer 66(1):e27454. https:\/\/doi.org\/10.1002\/pbc.27454","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"1176_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/pbc.21668","volume":"51","author":"C Rodriguez-Galindo","year":"2008","unstructured":"Rodriguez-Galindo C, Jeng M, Khuu P, McCarville MB, Jeha S (2008) Clofarabine in refractory Langerhans cell histiocytosis. Pediatr Blood Cancer 51(5):703\u2013706. https:\/\/doi.org\/10.1002\/pbc.21668","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"1176_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s12185-010-0558-0","volume":"91","author":"T Imamura","year":"2010","unstructured":"Imamura T, Sato T, Shiota Y, Kanegane H, Kudo K, Nakagawa S et al (2010) Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan. Int J Hematol 91(4):646\u2013651. https:\/\/doi.org\/10.1007\/s12185-010-0558-0","journal-title":"Int J Hematol"},{"key":"1176_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26784","author":"EA Yeh","year":"2018","unstructured":"Yeh EA, Greenberg J, Abla O, Longoni G, Diamond E, Hermiston M et al (2018) Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.26784","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"1176_CR19","first-page":"880","volume":"25","author":"D Prayer","year":"2004","unstructured":"Prayer D, Grois N, Prosch H, Gadner H, Barkovich AJ (2004) MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis. AJNR Am J Neuroradiol 25(5):880\u2013891","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"1176_CR20","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/ijlh.13304","volume":"42","author":"N Li","year":"2020","unstructured":"Li N, Cui L, Ma H, Gong Z, Lian H, Wang C et al (2020) Osteopontin is highly secreted in the cerebrospinal fluid of patient with posterior pituitary involvement in Langerhans cell histiocytosis. Int J Lab Hematol 42(6):788\u2013795. https:\/\/doi.org\/10.1111\/ijlh.13304","journal-title":"Int J Lab Hematol"},{"issue":"1324","key":"1176_CR21","first-page":"88","volume":"123","author":"D Garofalo","year":"2010","unstructured":"Garofalo D, Cutfield R (2010) Pituitary involvement in Langerhans-cell histiocytosis. N Z Med J 123(1324):88\u201391","journal-title":"N Z Med J"},{"issue":"25","key":"1176_CR22","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1200\/jco.2015.65.9508","volume":"34","author":"S H\u00e9ritier","year":"2016","unstructured":"H\u00e9ritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S et al (2016) BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol 34(25):3023\u20133030. https:\/\/doi.org\/10.1200\/jco.2015.65.9508","journal-title":"J Clin Oncol"},{"issue":"6","key":"1176_CR23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s12185-011-0965-x","volume":"94","author":"Y Shioda","year":"2011","unstructured":"Shioda Y, Adachi S, Imashuku S, Kudo K, Imamura T, Morimoto A (2011) Analysis of 43 cases of Langerhans cell histiocytosis (LCH)-induced central diabetes insipidus registered in the JLSG-96 and JLSG-02 studies in Japan. Int J Hematol 94(6):545\u2013551. https:\/\/doi.org\/10.1007\/s12185-011-0965-x","journal-title":"Int J Hematol"},{"key":"1176_CR24","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf. Accessed 29 Jan 2020"},{"issue":"2","key":"1176_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/pbc.20425","volume":"46","author":"N Grois","year":"2006","unstructured":"Grois N, Potschger U, Prosch H, Minkov M, Arico M, Braier J et al (2006) Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer 46(2):228\u2013233. https:\/\/doi.org\/10.1002\/pbc.20425","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"1176_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/00043426-200307000-00017","volume":"25","author":"F Ottaviano","year":"2003","unstructured":"Ottaviano F, Finlay JL (2003) Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine. J Pediatr Hematol Oncol 25(7):575\u2013577. https:\/\/doi.org\/10.1097\/00043426-200307000-00017","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"1176_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0360-3016(92)90006-4","volume":"23","author":"KJ Minehan","year":"1992","unstructured":"Minehan KJ, Chen MG, Zimmerman D, Su JQ, Colby TV, Shaw EG (1992) Radiation therapy for diabetes insipidus caused by Langerhans cell histiocytosis. Int J Radiat Oncol Biol Phys 23(3):519\u2013524. https:\/\/doi.org\/10.1016\/0360-3016(92)90006-4","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1176_CR28","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/modpathol.2013.181","volume":"27","author":"SL Yohe","year":"2014","unstructured":"Yohe SL, Chenault CB, Torlakovic EE, Asplund SL, McKenna RW (2014) Langerhans cell histiocytosis in acute leukemias of ambiguous or myeloid lineage in adult patients: support for a possible clonal relationship. Mod Pathol 27(5):651\u2013656. https:\/\/doi.org\/10.1038\/modpathol.2013.181","journal-title":"Mod Pathol"},{"issue":"4","key":"1176_CR29","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1084\/jem.20130977","volume":"211","author":"ML Berres","year":"2014","unstructured":"Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H et al (2014) BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 211(4):669\u2013683. https:\/\/doi.org\/10.1084\/jem.20130977","journal-title":"J Exp Med"},{"issue":"20","key":"1176_CR30","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1182\/blood-2013-06-511139","volume":"123","author":"DS Nelson","year":"2014","unstructured":"Nelson DS, Quispel W, Badalian-Very G, van Halteren AG, van den Bos C, Bovee JV et al (2014) Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood 123(20):3152\u20133155. https:\/\/doi.org\/10.1182\/blood-2013-06-511139","journal-title":"Blood"},{"issue":"10","key":"1176_CR31","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1182\/blood-2014-05-577361","volume":"124","author":"NA Brown","year":"2014","unstructured":"Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS et al (2014) High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood 124(10):1655\u20131658. https:\/\/doi.org\/10.1182\/blood-2014-05-577361","journal-title":"Blood"},{"issue":"1","key":"1176_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/pbc.20053","volume":"43","author":"KC Stine","year":"2004","unstructured":"Stine KC, Saylors RL, Saccente S, McClain KL, Becton DL (2004) Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 43(1):81\u201384. https:\/\/doi.org\/10.1002\/pbc.20053","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"1176_CR33","first-page":"255","volume":"25","author":"Z Adam","year":"2012","unstructured":"Adam Z, Szturz P, Duras J, Pour L, Krejci M, Rehak Z et al (2012) Treatment of Langerhans cells histiocytosis by cladribin reached long-term complete remission in 9 out of 10 adult patients. Klinicka Onkol 25(4):255\u2013261","journal-title":"Klinicka Onkol"},{"issue":"17","key":"1176_CR34","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1016\/j.ejca.2005.02.007","volume":"41","author":"F Bernard","year":"2005","unstructured":"Bernard F, Thomas C, Bertrand Y, Munzer M, Landman Parker J, Ouache M et al (2005) Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 41(17):2682\u20132689. https:\/\/doi.org\/10.1016\/j.ejca.2005.02.007","journal-title":"Eur J Cancer"},{"issue":"12","key":"1176_CR35","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1182\/blood-2015-03-635151","volume":"126","author":"J Donadieu","year":"2015","unstructured":"Donadieu J, Bernard F, van Noesel M, Barkaoui M, Bardet O, Mura R et al (2015) Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood 126(12):1415\u20131423. https:\/\/doi.org\/10.1182\/blood-2015-03-635151","journal-title":"Blood"},{"issue":"4","key":"1176_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/mpo.2950210406","volume":"21","author":"RM Egeler","year":"1993","unstructured":"Egeler RM, de Kraker J, Voute PA (1993) Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol 21(4):265\u2013270. https:\/\/doi.org\/10.1002\/mpo.2950210406","journal-title":"Med Pediatr Oncol"},{"issue":"1","key":"1176_CR37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/pbc.24061","volume":"59","author":"O Abla","year":"2012","unstructured":"Abla O, Palmert MR (2012) Reversal of LCH-related diabetes insipidus and reappearance of posterior pituitary bright spot with low-dose chemotherapy. Pediatr Blood Cancer 59(1):201\u2013202. https:\/\/doi.org\/10.1002\/pbc.24061","journal-title":"Pediatr Blood Cancer"},{"key":"1176_CR38","volume-title":"Langerhans cell histiocytosis treatment (PDQ(R)): Health Professional Version. PDQ Cancer Information Summaries","author":"PPPDQ Board","year":"2020","unstructured":"Board PPPDQ (2020) Langerhans cell histiocytosis treatment (PDQ(R)): Health Professional Version. PDQ Cancer Information Summaries. National Cancer Institute, Bethesda, MD"},{"key":"1176_CR39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1750-1172-8-72","volume":"8","author":"M Girschikofsky","year":"2013","unstructured":"Girschikofsky M, Arico M, Castillo D, Chu A, Doberauer C, Fichter J et al (2013) Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis 8:72. https:\/\/doi.org\/10.1186\/1750-1172-8-72","journal-title":"Orphanet J Rare Dis"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01176-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-021-01176-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01176-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T10:49:13Z","timestamp":1644230953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-021-01176-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,24]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1176"],"URL":"https:\/\/doi.org\/10.1007\/s11102-021-01176-x","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,24]]},"assertion":[{"value":"14 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Beijing Children\u2019s Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was waived because of the retrospective nature of the study. Informed consent of the treatment regimens was signed by every patient\u2019s guardian.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent to publish this information was obtained from study participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}